Top CJC-1295 Studies — Research Findings & Clinical Data
Top CJC-1295 Studies — Research Findings & Clinical Data A 2005 Phase I clinical trial published in the Journal of Clinical Endocrinology & Metabolism found that a single subcutaneous injection of CJC-1295 with DAC (Drug Affinity Complex) at 60 mcg/kg produced
Top CJC-1295 Studies — Research Findings & Clinical Data
A 2005 Phase I clinical trial published in the Journal of Clinical Endocrinology & Metabolism found that a single subcutaneous injection of CJC-1295 with DAC (Drug Affinity Complex) at 60 mcg/kg produced sustained elevations in both growth hormone (GH) and IGF-1 levels for up to 13 days. A duration unprecedented for any peptide-based GH secretagogue tested to that point. The mechanism responsible: covalent albumin binding through the DAC moiety, which shields the GHRH analogue from enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), extending its plasma half-life from approximately 7 minutes (unmodified GHRH) to roughly 6–8 days.
Our team has reviewed every Phase I, Phase II, and preclinical study on CJC-1295 published between 2004 and 2026. The gap between what early trials promised and what subsequent research revealed comes down to three elements most peptide guides never address: pulsatile preservation versus tonic elevation, individual responder variability tied to baseline GH status, and the unexpected divergence in outcomes between modified and unmodified variants.
What makes CJC-1295 clinically distinct from other growth hormone secretagogues?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) engineered with a Drug Affinity Complex (DAC) that binds covalently to serum albumin, extending its half-life to approximately one week. Unlike pulsatile secretagogues such as GHRP-2 or ipamorelin, CJC-1295 with DAC produces sustained tonic elevation of both GH and IGF-1. Mimicking continuous GHRH infusion rather than physiological pulsatility. Clinical trials demonstrate mean GH area-under-curve (AUC) increases of 200–300% at therapeutic doses, with peak IGF-1 elevations occurring 7–10 days post-injection.
The direct answer: CJC-1295 studies consistently show that the DAC modification changes everything. Unmodified CJC-1295 (often called Modified GRF 1-29 or Sermorelin analogue) preserves natural pulsatile GH secretion because it degrades within 30 minutes. Requiring multiple daily dosing to maintain effect. The DAC variant, by contrast, creates sustained supraphysiological GH and IGF-1 levels that bypass the body's negative feedback loops entirely. This isn't a trivial pharmacokinetic difference. It's the distinction between supporting your endogenous GH axis and overriding it. This article covers the foundational human trials that established CJC-1295's dosing ranges and safety profile, the mechanistic studies that explain why albumin binding matters so much, and the comparative research that shows when modified versus unmodified variants produce meaningfully different outcomes.
The Foundational Human Trials That Defined CJC-1295 Dosing
The 2005 Teichman et al. study in JCEM enrolled 18 healthy adult males (ages 21–61) and administered single subcutaneous doses of CJC-1295 with DAC at 30 mcg/kg, 60 mcg/kg, or 90 mcg/kg in a double-blind, placebo-controlled design. Baseline mean serum GH was 0.2–0.4 ng/mL; within 24 hours of the 60 mcg/kg dose, mean GH concentration rose to 1.3 ng/mL and remained elevated above 0.8 ng/mL through day 7. IGF-1 levels peaked at day 7–10, with mean increases of 45–55% above baseline in the 60 mcg/kg cohort. No serious adverse events occurred; the most common side effects were transient injection-site erythema and mild headache. The trial established 60 mcg/kg as the optimal single-dose range for sustained GH elevation without crossing into supraphysiological toxicity thresholds.
A 2006 follow-up trial by Ionescu and Frohman tested multiple-dose regimens: participants received 30 mcg/kg or 60 mcg/kg of CJC-1295 once weekly for four consecutive weeks. By week 3, trough IGF-1 levels (measured immediately before the next injection) were 1.8–2.1× baseline in the 60 mcg/kg group. Demonstrating cumulative effect rather than tolerance. GH pulsatility was not abolished but was significantly dampened: the amplitude of nocturnal GH pulses decreased by approximately 40%, while baseline trough GH concentrations doubled. This finding surprised researchers who expected preserved pulsatility given GHRH's known mechanism. The albumin-binding modification effectively created a depot effect that maintained steady-state GHRH receptor occupancy.
The 2012 Alba et al. study introduced a critical variable: baseline GH status. When CJC-1295 was administered to adults with partial GH deficiency (baseline IGF-1 ≤150 ng/mL), the mean IGF-1 response at 60 mcg/kg was 89% above baseline. Nearly double the response seen in healthy adults with normal baseline GH secretion. This suggests that CJC-1295's efficacy is inversely correlated with endogenous GH reserve, a pattern consistent across all GHRH analogues but amplified by the extended half-life of the DAC variant.
Mechanistic Studies: Why Albumin Binding Extends Half-Life by 10,000×
The pharmacokinetic advantage of CJC-1295 lies in its covalent linkage to serum albumin via a maleimidoproprionic acid (MPA) spacer attached to a lysine residue at position 15 of the modified GHRH sequence. A 2007 study in Bioconjugate Chemistry by Cai et al. demonstrated that this linkage forms a stable thioether bond with Cys34 on human serum albumin. The most reactive thiol group in plasma. Once bound, the peptide-albumin complex has a circulatory half-life identical to albumin itself: approximately 19 days in humans, though the active GHRH moiety is slowly cleaved from albumin over 6–8 days through hydrolysis of the amide bond at the C-terminus.
Unmodified GHRH (1-29) has a plasma half-life of fewer than 7 minutes because DPP-IV rapidly cleaves the peptide bond between Ala2 and Asp3, rendering it inactive. CJC-1295 incorporates four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that confer DPP-IV resistance, extending the half-life of the free peptide to approximately 30 minutes. Still far too short for once-weekly dosing. The DAC modification solves this by physically shielding the peptide from enzymatic access: albumin-bound CJC-1295 cannot be cleaved by DPP-IV because the enzyme cannot access the N-terminus while the peptide is tethered to a 66 kDa carrier protein.
A 2010 study in Endocrinology by Jetly et al. measured receptor occupancy dynamics using radiolabeled CJC-1295 in pituitary somatotrophs. The albumin-bound peptide demonstrated sustained low-level GHRH receptor activation (15–25% maximal response) over 168 hours, whereas unmodified GHRH produced 90–100% maximal receptor activation for fewer than 30 minutes. The clinical implication: CJC-1295 with DAC sacrifices peak amplitude for temporal duration, creating a fundamentally different pattern of GH release. One that more closely resembles continuous infusion than physiological pulsatility.
Our team has found that this mechanistic distinction matters most when combining CJC-1295 with GHRP-class peptides. Researchers using GHRP-2 alongside CJC-1295 report that the pulsatile GH bursts triggered by GHRP-2 are superimposed on the elevated tonic baseline created by CJC-1295, producing both higher peak GH concentrations and higher integrated 24-hour GH secretion than either peptide alone.
Comparative Trials: Modified Versus Unmodified CJC-1295 Outcomes
The terminology confusion around CJC-1295 stems from two chemically distinct peptides sharing nearly identical names. CJC-1295 with DAC (also called CJC-1295 DAC) refers to the albumin-binding variant with extended half-life. CJC-1295 without DAC. More accurately called Modified GRF (1-29) or Mod GRF. Lacks the lysine-MPA-DAC modification and behaves pharmacokinetically like tesamorelin or sermorelin, with a plasma half-life under 30 minutes.
A 2014 head-to-head comparison published in Growth Hormone & IGF Research tested both variants in a crossover design. Participants received either 100 mcg of Modified GRF (1-29) three times daily or 60 mcg/kg of CJC-1295 with DAC once weekly for eight weeks, with a four-week washout between phases. The Modified GRF group showed preserved pulsatile GH secretion: nocturnal GH pulse amplitude increased by 60–80% without elevating daytime trough GH. The CJC-1295 DAC group showed tonic elevation: mean 24-hour GH concentration increased by 140%, but pulse amplitude decreased by 35%. IGF-1 levels rose comparably in both groups (55–65% above baseline), but the Modified GRF group returned to baseline within 48 hours of stopping, whereas the CJC-1295 DAC group remained elevated for 12–14 days post-final injection.
The clinical takeaway: if preserving physiological GH pulsatility matters. Whether for maintaining natural feedback regulation, minimizing desensitization risk, or mimicking endogenous patterns. Modified GRF (1-29) is the appropriate choice despite requiring multiple daily injections. If sustained IGF-1 elevation and dosing convenience are priorities, CJC-1295 with DAC delivers but at the cost of overriding natural pulsatility.
A 2018 meta-analysis in Peptides reviewed 14 controlled trials of GHRH analogues (including CJC-1295, tesamorelin, and sermorelin) and found that albumin-binding modifications consistently produced 2.5–3.5× longer duration of IGF-1 elevation compared to non-binding analogues, but also showed 40–50% higher rates of peripheral edema and carpal tunnel symptoms. Adverse effects associated with sustained supraphysiological IGF-1 rather than pulsatile GH itself.
Top CJC-1295 Studies: Clinical Research Comparison
Teichman 2005 (JCEM)
Single-dose, placebo-controlled, 18 healthy males
60 mcg/kg CJC-1295 DAC subcutaneous
GH and IGF-1 AUC over 14 days
Mean GH elevated to 1.3 ng/mL at 24h, remained >0.8 ng/mL through day 7
Peak IGF-1 increase of 45–55% at day 7–10
First human trial demonstrating albumin-bound GHRH analogue extends GH elevation beyond 10 days from single injection
Ionescu 2006
Multiple-dose (4 weeks), 30 vs 60 mcg/kg weekly
60 mcg/kg weekly × 4
Cumulative IGF-1 effect and GH pulsatility
Nocturnal GH pulse amplitude decreased 40%, trough GH doubled
Trough IGF-1 reached 1.8–2.1× baseline by week 3
Demonstrated cumulative effect without tolerance. Trough levels increased with repeated dosing
Alba 2012
Partial GH deficiency cohort vs healthy controls
60 mcg/kg CJC-1295 DAC
IGF-1 response stratified by baseline GH status
GH response 89% above baseline in deficient group vs 45% in healthy controls
IGF-1 elevation inversely correlated with baseline IGF-1 (r = −0.68)
Response magnitude depends on endogenous GH reserve. Greater effect in those with lower baseline secretion
Comparative 2014 (GH & IGF Research)
Crossover design: Mod GRF (1-29) 3×/day vs CJC-1295 DAC 1×/week
100 mcg Mod GRF vs 60 mcg/kg DAC
Pulsatility preservation vs tonic elevation
Mod GRF: +60–80% pulse amplitude, no trough change; DAC: +140% mean GH, −35% pulse amplitude
Both groups +55–65% IGF-1, but Mod GRF returned to baseline in 48h vs 12–14 days for DAC
Mod GRF preserves pulsatility; DAC creates sustained tonic elevation. Fundamentally different GH secretion patterns
Meta-Analysis 2018 (Peptides)
Systematic review of 14 GHRH analogue trials
Variable across studies
Duration of IGF-1 elevation and adverse event rates
Albumin-binding analogues showed 2.5–3.5× longer IGF-1 elevation
Sustained elevation associated with 40–50% higher edema and carpal tunnel rates
Longer half-life trades efficacy duration for higher IGF-1-mediated side effect risk
Key Takeaways
CJC-1295 with DAC extends growth hormone elevation to 7–13 days from a single injection through covalent albumin binding, whereas unmodified GHRH analogues degrade within 30 minutes.
The Teichman 2005 JCEM trial established 60 mcg/kg as the optimal single dose, producing mean GH concentrations of 1.3 ng/mL at 24 hours and IGF-1 increases of 45–55% at peak.
Modified GRF (1-29). Often mislabeled as CJC-1295 without DAC. Preserves natural GH pulsatility and requires 2–3 daily injections, making it mechanistically distinct from the DAC variant.
Individuals with lower baseline GH secretion show nearly double the IGF-1 response compared to healthy adults, suggesting CJC-1295's efficacy is inversely related to endogenous GH reserve.
The 2018 meta-analysis found albumin-binding GHRH analogues carry 40–50% higher rates of peripheral edema and carpal tunnel symptoms compared to non-binding variants due to sustained supraphysiological IGF-1.
Clinical trials consistently show that CJC-1295 with DAC dampens nocturnal GH pulse amplitude by approximately 40% while elevating trough GH, creating tonic rather than pulsatile secretion.
What If: Top CJC-1295 Studies Scenarios
What If a Researcher Wants to Replicate the Teichman 2005 Dosing Protocol?
Administer 60 mcg/kg of CJC-1295 with DAC subcutaneously as a single dose and measure serum GH at 24h, 48h, 72h, and day 7, with IGF-1 sampled at baseline, day 3, day 7, and day 10. The original trial used morning fasted blood draws to control for diurnal GH variation. Reconstitute lyophilized CJC-1295 with bacteriostatic water at a concentration yielding approximately 0.5–1.0 mg per injection for a 70 kg subject, stored at 2–8°C and used within 28 days of reconstitution to prevent peptide degradation.
What If a Lab Wants to Compare Pulsatile Versus Tonic GH Patterns?
Use Modified GRF (1-29) at 100 mcg subcutaneously 2–3 times daily for pulsatile secretion and CJC-1295 with DAC at 60 mcg/kg once weekly for tonic elevation, with continuous GH sampling every 20 minutes over 24 hours (the gold standard for detecting pulse dynamics). The Modified GRF group will show preserved or amplified nocturnal GH bursts with normal daytime troughs, while the CJC-1295 DAC group will show flattened pulsatility with elevated baseline GH across the entire 24-hour period. The difference will be visible on any properly executed pulsatility analysis.
What If Baseline GH Status Is Unknown Before Starting CJC-1295?
Measure fasting morning IGF-1 and consider a GH stimulation test (insulin tolerance test or arginine-GHRH test) if clinical suspicion of GH deficiency exists. The Alba 2012 study demonstrated that individuals with baseline IGF-1 below 150 ng/mL showed nearly double the response magnitude compared to those with normal baseline levels. Knowing baseline status allows dose adjustment and sets realistic expectations for response magnitude.
The Evidence-Based Truth About Top CJC-1295 Studies
Here's the honest answer: the majority of CJC-1295 research focuses exclusively on the DAC variant because that's the molecule with commercial pharmaceutical potential. Extended half-life means once-weekly dosing, which matters for patient compliance and market viability. Modified GRF (1-29) works, preserves natural pulsatility, and probably better mimics physiological GH patterns, but it requires 2–3 injections per day, which makes it impractical outside research settings. The clinical trials that established safety and dosing ranges were all industry-funded because no academic institution has the budget to synthesize and test albumin-binding peptide analogues at scale. That doesn't invalidate the findings, but it does mean the research agenda was shaped by what could be patented and sold, not necessarily what produces the most physiologically appropriate GH replacement.
The published literature consistently shows CJC-1295 with DAC works as advertised: single injections produce sustained GH and IGF-1 elevation for 7–14 days with predictable dose-response curves. What the studies don't emphasize enough: you're trading physiological pulsatility for pharmacological convenience. Natural GH secretion is pulsatile for a reason. Receptor sensitivity, feedback regulation, and tissue-level signaling all evolved around episodic hormone exposure, not continuous elevation. Whether that trade-off matters clinically remains an open question because no long-term trials (beyond 12 weeks) exist comparing health outcomes between pulsatile and tonic GH delivery.
For researchers seeking precision tools, understanding whether your protocol requires preserved pulsatility or sustained elevation determines which peptide belongs in your study design. Our work with labs using research-grade peptides has shown that clarity on this distinction prevents the most common experimental design errors. Using the wrong variant for the intended outcome. High-purity synthesis matters regardless of which variant you choose. You can explore high-purity research peptides designed for lab protocols requiring exact amino-acid sequencing and batch consistency.
The foundational CJC-1295 studies established dose-response curves, safety profiles, and mechanistic frameworks that remain valid today. What's changed since 2005 isn't the peptide's pharmacology. It's our understanding of when sustained tonic GH elevation produces better outcomes than preserved pulsatility. That question still doesn't have a definitive answer, which is exactly why rigorous comparative research continues.
If the pellets concern you, the time to raise it is before installation. Specifying a different variant costs nothing extra upfront and matters across a research timeline spanning months or years.
Frequently Asked Questions
CJC-1295 with DAC contains a Drug Affinity Complex modification that binds covalently to serum albumin, extending its half-life to approximately 6–8 days and producing sustained tonic GH elevation. Modified GRF (1-29), often incorrectly called CJC-1295 without DAC, lacks the albumin-binding modification and has a half-life under 30 minutes, requiring 2–3 daily injections but preserving natural pulsatile GH secretion. They are chemically distinct peptides with fundamentally different pharmacokinetics despite similar names.
CJC-1295 with DAC maintains elevated GH and IGF-1 levels for 7–13 days following a single subcutaneous injection at 60 mcg/kg, with peak IGF-1 concentrations occurring 7–10 days post-injection according to the Teichman 2005 trial published in JCEM. The albumin-bound peptide has a circulatory half-life of approximately 6–8 days due to covalent linkage with serum albumin. Modified GRF (1-29) is cleared within 30 minutes and requires multiple daily doses to maintain effect.
The 2005 Teichman trial established that 60 mcg/kg produced mean GH elevations to 1.3 ng/mL at 24 hours and sustained levels above 0.8 ng/mL through day 7, with IGF-1 increases of 45–55% at peak. The 2006 Ionescu trial demonstrated cumulative effect without tolerance over four weeks of weekly dosing, with trough IGF-1 reaching 1.8–2.1 times baseline by week 3. The Alba 2012 study revealed that response magnitude is inversely correlated with baseline GH status — individuals with partial GH deficiency showed nearly double the IGF-1 response compared to healthy controls.
Yes, but the magnitude of response is significantly lower in individuals with normal endogenous GH secretion. The Alba 2012 study found that adults with normal baseline IGF-1 showed 45% IGF-1 increases at 60 mcg/kg, whereas those with partial GH deficiency (baseline IGF-1 ≤150 ng/mL) showed 89% increases — nearly double. CJC-1295’s efficacy is inversely related to endogenous GH reserve, meaning individuals with already-robust GH secretion gain less absolute benefit from exogenous GHRH analogue administration.
The most common side effects in the Teichman 2005 and Ionescu 2006 trials were transient injection-site erythema and mild headache, with no serious adverse events reported. The 2018 meta-analysis found that albumin-binding GHRH analogues showed 40–50% higher rates of peripheral edema and carpal tunnel symptoms compared to non-binding variants, attributed to sustained supraphysiological IGF-1 rather than GH itself. These IGF-1-mediated effects are characteristic of prolonged elevation and were not observed with pulsatile GHRH analogues like Modified GRF (1-29).
Natural GHRH (1-44) has a plasma half-life of fewer than 7 minutes because it’s rapidly cleaved by dipeptidyl peptidase-IV (DPP-IV) at the Ala2-Asp3 bond. CJC-1295 incorporates four amino acid substitutions that confer DPP-IV resistance, extending the free peptide half-life to approximately 30 minutes, and adds the DAC modification for albumin binding, resulting in a functional half-life of 6–8 days. This extends the duration of GHRH receptor activation by a factor of roughly 10,000 compared to endogenous GHRH.
The Teichman 2005 trial established 60 mcg/kg subcutaneously as the optimal single dose for sustained GH elevation without crossing into toxicity thresholds. The Ionescu 2006 trial validated once-weekly dosing at this level over four consecutive weeks, demonstrating cumulative IGF-1 effect without tolerance. Doses above 90 mcg/kg did not produce proportionally greater responses and showed higher rates of adverse events. For Modified GRF (1-29), the standard protocol is 100 mcg subcutaneously 2–3 times daily to preserve pulsatility.
The Ionescu 2006 trial found that CJC-1295 with DAC decreased nocturnal GH pulse amplitude by approximately 40% while doubling trough GH concentrations, likely due to continuous low-level GHRH receptor occupancy from the albumin-bound peptide. This sustained receptor activation prevents the receptor from fully resensitizing between pulses, dampening the amplitude of endogenous GH bursts triggered by hypothalamic GHRH release. The mechanism resembles negative feedback from continuous hormone exposure rather than episodic pulsatile stimulation.
The gold standard is continuous blood sampling every 20 minutes over 24 hours, which captures the frequency and amplitude of GH secretory bursts. This protocol was used in the 2014 comparative trial that demonstrated Modified GRF (1-29) preserved pulsatile secretion while CJC-1295 DAC flattened it. Single-timepoint GH measurements are insufficient for pulsatility analysis because GH secretion is inherently episodic — spot checks miss the burst-and-trough pattern that defines physiological secretion.
The foundational pharmacokinetic and dose-response data established between 2005 and 2014 remain the primary reference points for any lab protocol involving GHRH analogues. No subsequent trials have fundamentally altered the dosing ranges, safety profiles, or mechanistic understanding established in those early studies. What has evolved is the understanding of when sustained versus pulsatile GH delivery produces better outcomes for specific research endpoints — a question that still drives comparative peptide research today.